Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Professor Paul Glue

Paul GlueProfessor Paul Glue's research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. Biomarkers for anxiety and the technical aspects of clinical trial design, including trialing simulation and modeling are other areas of interest. He has published extensively, with more than 300 papers, book chapters and abstracts to his name.

Find out more about Professor Paul Glue’s research.

^ Top of page

Publications

Barak, Y., Barson, D., Davie, G., Glue, P., & Paleacu, D. (2020). Internalize at your peril: Internalizing disorders as risk factors for dementia: Cohort study. GeroScience. Advance online publication. doi: 10.1007/s11357-020-00285-y

Short, B., Dong, V., Gálvez, V., Vulovic, V., Martin, D., Bayes, A. J., … Glue, P., … Loo, C. K. (2020). Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 266, 615-620. doi: 10.1016/j.jad.2020.01.120

Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2020). Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology. Advance online publication. doi: 10.1177/0269881120953991

Lenagh-Glue, J., Thom, K., O'Brien, A., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2020). The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. International Journal of Law & Psychiatry, 68, 101537. doi: 10.1016/j.ijlp.2019.101537

Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology, 10, 1-6. doi: 10.1177/2045125320922474

Chapter in Book - Research

De Ridder, D., Manning, P., Cape, G., Vanneste, S., Langguth, B., & Glue, P. (2016). Pathophysiology-based neuromodulation for addictions: An overview. In V. R. Preedy (Ed.), Neuropathology of drug addictions and substance misuse (Vol. 1: Foundations of understanding, tobacco, alcohol, cannabinoids and opioids). (pp. 14-24). London: Elsevier. doi: 10.1016/B978-0-12-800213-1.00002-X

Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. A. R. (2013). Mandatory second opinions on compulsory treatment. In J. Dawson & K. Gledhill (Eds.), New Zealand's Mental Health Act in practice. (pp. 229-246). Wellington, New Zealand: Victoria University Press.

^ Top of page

Journal - Research Article

Barak, Y., Barson, D., Davie, G., Glue, P., & Paleacu, D. (2020). Internalize at your peril: Internalizing disorders as risk factors for dementia: Cohort study. GeroScience. Advance online publication. doi: 10.1007/s11357-020-00285-y

Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology, 10, 1-6. doi: 10.1177/2045125320922474

Lenagh-Glue, J., Thom, K., O'Brien, A., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2020). The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. International Journal of Law & Psychiatry, 68, 101537. doi: 10.1016/j.ijlp.2019.101537

Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2020). Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology. Advance online publication. doi: 10.1177/0269881120953991

Short, B., Dong, V., Gálvez, V., Vulovic, V., Martin, D., Bayes, A. J., … Glue, P., … Loo, C. K. (2020). Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 266, 615-620. doi: 10.1016/j.jad.2020.01.120

Neumann, S. R., Glue, P., & Linscott, R. J. (2020). Aberrant salience and reward processing: A comparison of measures in schizophrenia and anxiety. Psychological Medicine. Advance online publication. doi: 10.1017/s0033291720000264

Barak, Y., Neehoff, S., & Glue, P. (2020). Ageing badly: Indicators of old-age structure in Australia and New Zealand. Journal of Primary Health Care, 12(3), 272-276. doi: 10.1071/hc19095

Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267-272. doi: 10.1177/0269881119874457

Leong, S. L., Glue, P., Manning, P., Vanneste, S., Lim, L. J., Mohan, A., & De Ridder, D. (2020). Anterior cingulate cortex implants for alcohol addiction: A feasibility study. Neurotherapeutics. Advance online publication. doi: 10.1007/s13311-020-00851-4

Barak, Y., Leitch, S., & Glue, P. (2020). The Great Escape: Centenarians' exceptional health. Aging Clinical & Experimental Research. Advance online publication. doi: 10.1007/s40520-020-01552-w

Barak, Y., Cheung, G., Fortune, S., & Glue, P. (2020). No country for older men: Ageing male suicide in New Zealand. Australasian Psychiatry. Advance online publication. doi: 10.1177/1039856220905304

Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N., & Hung, C. T. (2020). Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 60(6), 751-757. doi: 10.1002/jcph.1573

Shadli, S. M., High, O., Byers, B., Gibbs, P., Steller, R., Glue, P., & McNaughton, N. (2019). Human anxiety-specific "theta" occurs with selective stopping and localizes to right inferior frontal gyrus. Behavioral Neuroscience. Advance online publication. doi: 10.1037/bne0000316

Allwood, C., O'Brien, A., & Glue, P. (2019). Referrals from primary care to community mental health teams: What's missing? Journal of Primary Health Care, 11(4), 334-341. doi: 10.1071/HC19053

Gale, C., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019). Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(5), 543-547. doi: 10.1177/0269881118822146

Thom, K., Lenagh-Glue, J., O'Brien, A. J., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2019). Service user, whānau and peer support workers' perceptions of advance directives for mental health. International Journal of Mental Health Nursing, 28, 1296-1305. doi: 10.1111/inm.12637

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., Broughton, L., & Medlicott, N. (2018). Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Delivery & Translational Research, 8(3), 780-786. doi: 10.1007/s13346-017-0476-2

Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., … Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression: The way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407. doi: 10.1177/0269881118760660

Menkes, D. B., Glue, P., Gale, C., Lam, F., Hung, C.-T., & Hung, N. (2018). Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients. EBioMedicine, 27, 134-137. doi: 10.1016/j.ebiom.2017.11.030

Leitch, S., Glue, P., Gray, A. R., Greco, P., & Barak, Y. (2018). Comparison of psychosocial variables associated with loneliness in centenarian vs elderly populations in New Zealand. JAMA Network Open, 1(6), e183880. doi: 10.1001/jamanetworkopen.2018.3880

Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667. doi: 10.1177/0269881118762073

Shadli, S. M., Kawe, T., Martin, D., McNaughton, N., Neehoff, S., & Glue, P. (2018). Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. International Journal of Neuropsychopharmacology, 21(8), 717-724. doi: 10.1093/ijnp/pyy032

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., & Medlicott, N. J. (2018). The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. Journal of Psychopharmacology, 32(10), 1127-1132. doi: 10.1177/0269881118780013

Lenagh-Glue, J., O'Brien, A., Dawson, J., Thom, K., Potiki, J., Casey, H., & Glue, P. (2018). A MAP to mental health: The process of creating a collaborative advance preferences instrument. New Zealand Medical Journal, 131(1486), 18-26. Retrieved from https://www.nzma.org.nz/journal

Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1302-1305. doi: 10.1177/0269881117705089

George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., … Glue, P., … Loo, C. K. (2017). Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. American Journal of Geriatric Psychiatry, 25(11), 1199-1209. doi: 10.1016/j.jagp.2017.06.007

Castle, C., Gray, A., Neehoff, S., & Glue, P. (2017). Effect of ketamine dose on self-rated dissociation in patients with treament refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1306-1311. doi: 10.1177/0269881117725685

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., … Harland, S., … Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460-468. doi: 10.1002/cpdd.254

Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., … Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15. doi: 10.1093/ijnp/pyv124

Shadli, S. M., Smith, M. J., Glue, P., & McNaughton, N. (2016). Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. Biological Psychology, 117, 50-55. doi: 10.1016/j.biopsycho.2016.02.011

Whigham, P. A., de Graaf, B., Srivastava, R., & Glue, P. (2016). Managing distance and covariate information with point-based clustering. BMC Medical Research Methodology, 16(1), 115. doi: 10.1186/s12874-016-0218-z

French, J., Glue, P., Friedman, D., Almas, M., Yardi, N., Knapp, L., … Posner, H. B. (2016). Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology, 87(12), 1242-1249. doi: 10.1212/wnl.0000000000003118

Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi-Pavlovic, D., Leyden, J., … Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56. doi: 10.1111/acps.12572

De Ridder, D., Vanneste, S., Gillett, G., Manning, P., Glue, P., & Langguth, B. (2016). Psychosurgery reduces uncertainty and increases free will? A review. Neuromodulation, 19, 239-248. doi: 10.1111/ner.12405

Courts, J., Maskill, V., Gray, A., & Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review. Australasian Psychiatry, 24(6), 598-601. doi: 10.1177/1039856216663733

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Gray, A., Hung, N., … Harland, S., … Friedhoff, L. (2016). Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. Journal of Clinical Pharmacology, 56(8), 960-965. doi: 10.1002/jcph.704

Glue, P., Courts, J., Gray, A., & Patterson, T. (2016). Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. New Zealand Medical Journal, 129(1433), 41-44. Retrieved from http://www.nzma.org.nz/journal

Forsyth, B., Machado, L., Jowett, T., Jakobi, H., Garbe, K., Winter, H., & Glue, P. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 189, 10-13. doi: 10.1016/j.jep.2016.05.022

Glue, P., Courts, J., Gale, C., & Mason, E. (2015). Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. New Zealand Medical Journal, 128(1414). Retrieved from https://www.nzma.org.nz/journal

Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C.-T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55(2), 189-194. doi: 10.1002/jcph.404

Glue, P., & Herbison, P. (2015). Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Australian & New Zealand Journal of Psychiatry, 49(12), 1215-1220. doi: 10.1177/0004867415614109

Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. T. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680-687. doi: 10.1002/jcph.471

Dawson, J., Glue, P., Ellis, P. M., Lenagh-Glue, J., Goldsmith, D., & Smith, D. A. R. (2015). Lessons from export to New Zealand of the second opinion appointed doctor scheme. BJPsych Bulletin, 39(2), 69-73. doi: 10.1192/pb.bp.113.046540

Shadli, S. M., Glue, P., McIntosh, J., & McNaughton, N. (2015). An improved human anxiety process biomarker: Characterization of frequency band, personality and pharmacology. Translational Psychiatry, 5, e699. doi: 10.1038/tp.2015.188

Gupta, S. K., Kantesaria, B., & Glue, P. (2014). Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries & Therapeutics, 8(2), 89-95. doi: 10.5582/ddt.8.89

Shelker, W., Poole, P., Bagg, W., Wood, I., & Glue, P. (2014). Postgraduation retention of medical students from Otago and Auckland medical programmes. New Zealand Medical Journal, 127(1388). Retrieved from http://www.nzma.org.nz/journal

Shelker, W., Zaharic, T., Sijnja, B., & Glue, P. (2014). Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. New Zealand Medical Journal, 127(1403). Retrieved from http://www.nzma.org.nz/journal

Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., … Loo, C. K. (2014). Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World Journal of Psychiatry, 15(7), 579-584. doi: 10.3109/15622975.2014.922697

More publications...